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The adenomatous polyposis coli (APC) gene, localized on 
chromosome 5, consists of 15 exons. The largest is the 
exon 15, which comprises more than 75% of the coding 
sequence of the gene and is the most common target for 
both germline and somatic mutations (Groden et al, 1993). 
The germline mutations in the APC gene are in charge of 
the familial adenomatous polyposis (FAP), a rare 
autosomal inherited disease (Hegde and Roa, 2006). These 
mutations predispose to develop colonic polyps and other 
extraintestinal neoplasms, including desmoid tumour in 
subjects between 15 and 60 years. The estimated risk of 
developing a desmoid tumour in patients with FAP is 
between 4 and 20 percent. This risk increases about 2 
years after colectomy (Groen et al, 2008). 
 
We studied a woman (56 years old) affected with FAP and 
desmoid tumour and her three children (two daughters and 
one son). This study was carried out in accordance with 
the World Medical Association Helsinki Declaration, 
adopted in 1964 and amended in 1975, 1983, 1989, 1996 
and 2000 (World Medical Association, 1998). Informed 
consents were obtained from all subjects, and the study 
was approved and conducted according to the ethical 
guidelines of the Second School of Naples. The pedigree 
was generated by the genetic counsellor and the case-
histories of the subjects were collected. 
 
The pedigree and the main clinical data are summarised in 
Figure 1. The family originated from the Campania, a 
region of southern Italy. The proband affected with FAP 
had surgical treatment with restorative proctocolectomy 
and ileal J-pouch at the age of 54 years. Two years after 
the pouch procedure the proband developed desmoid 
tumour, consistent with previous reports (for example, 
Groen et al, 2008). 
 
Out of three children of proband, a daughter and a son 
were affected with FAP, diagnosed at the ages of 28 year 
and 18 year, respectively. Both siblings received ileal J-
pouch procedure. The eldest daughter (33 years old) did 
not display the disease phenotype. 
 
56 yrs 
1605_1606delTG
29 yrs
1605_1606delTG
33 yrs 19 yrs
1605_1606delTG
4 yrs  
 
Figure 1. Pedigree of family with APC mutation identified. The 
arrow indicates the proband. Open symbols, clinically unaffected 
subjects; right inferior quadrate blackened symbols, patients 
affected with FAP; left superior quadrate blackened symbols, 
patients affected with desmoid tumours.    236 
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Peripheral blood from subjects was collected using 
standard procedures and all 15 exons of the APC gene and 
the flanking splice site regions were amplified using a set 
of 28 primer pairs (Table 1). One set of primers was used 
to amplify each exon and the adjacent intronic region 
except for exon 15, which was amplified as 14 separate 
PCR fragments due to it large size. 
 
PCR products were sequenced using the ABI PRISM di-
Deoxy Terminator Cycle sequencing kit in an ABI 9700 
Thermal Cyclers and ABI PRISM 310 Genetic Analyzer. 
Deviations from the wild-type sequence were identified 
using Mutation Surveyor, sequence analysis and assembly 
software. 
 
The analysis of the APC gene in the DNA sample from 
proband revealed the presence of the novel deletion, 
1605_1606delTG. This frameshift mutation is located in 
exon 12 of APC gene and is characterized by a deletion of 
two nucleotides, generating a premature stop codon 
between codons 537 and 538 (Figure 2). The presence of 
the mutation was confirmed by resequencing a second 
DNA sample from the patient. 
 
The genetic analysis conducted in family members showed 
the same mutation in the daughter and the son affected 
with FAP, while the healthy daughter did not have this 
mutation (Figure 1). 
 
In this study, we identified in the proband, affected with 
FAP and desmoid tumour the novel mutation 
1605_1606delTG. The proband passed on the mutation to 
one of her daughters and the son resulting in FAP 
phenotype. The different onset age of FAP in proband, 
daughter and son (54, 28 and 18 years, respectively) 
indicates intrafamilial variability. In the FAP, the sites of 
the mutation determine the presence or the absence of 
extracolonic manifestation of the disease, as desmoid 
tumours. The identified frameshift mutation is located in 
exon 12 at codon 535 in the 5’end of APC gene, a region 
of APC gene not usually associated with desmoid tumor. 
Indeed, the previous studies show that in patients affected 
with FAP and desmoid tumour the mutations of APC gene 
are localized predominantly in exon 15 (Lips et al, 2009). 
It is possible that the site of the mutation may also 
influence the severity of desmoid phenotype (Couture et 
al, 2000). It has been previously reported that the most 
severe desmoid phenotype (penetrance=100%) presents in 
families which carry mutations in the 3’ end of the APC 
gene (Eccles et al, 2001). 
 
In the proband, after three months of medical treatment 
with Toremifene, a selective oestrogen receptor modulator, 
the abdominal ultrasound showed no detectable 
hydronephrosis and the magnetic resonance imaging 
documented a downsizing of the mass. These data suggest 
that the mutations that are not in the 3’ end of the APC 
gene may be associated with a less severe phenotype. 
 
Both siblings affected with FAP and positive for APC 
gene mutation received colectomy nearly an year ago and 
at present are undergoing a clinical follow-up program. 
We propose that a longer follow-up could clarify the 
association between this novel mutation and the 
development of desmoid tumour. The identification of this 
novel mutation in APC gene and the outcome of the 
clinical follow-up of the subjects of this study are likely to 
be helpful in the FAP patient treatment and care strategies 
in the future. 
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Gene  Exon  mRNA nt  Base change  Amino acid change  Designation  Mutation type 
APC  12  1605-1606  delTG  STOP-codon 537-538  1605_1606delTG  frameshift 
 
A :           B :  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Carrier frameshift variant c.1605_1606delTG. Electropherogram for the sense strand of exon 12 of APC gene. DNA 
sequence reveals a heterozygous TG nucleotide deletion (A), resulting in frameshift and subsequent chain termination. The wide type 
sequence is shown in (B). 237 
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Table 1. APC Primer sequences (Amplification conditions: : 94°C for 30sec, 62°C for 60sec, 72°C for 60sec, 35 cycles). 
 
Name 
 
Primer sequence (5’ to 3’) 
 
Product size 
1-f  GCATATTAACACAATTCTTCTTAAACGTC 
327 
1-r  GAATACTGAATAAAAATGGATAAACTACAATTAAA 
2-f  GTCAAGAAATACAGAATCATGTCTTGAA 
223 
2-r  TCTACACACCTAAAGATGACAATTTGAG 
3-f  GACCCAAGTGGACTTTTCAGG 
423 
3-r  ACAATAAACTGGAGTACACAAGGCA 
4-f  TGCTCTTCTGCAGTCTTTATTAGCA 
255 
4-r  CCTGAATTTTAATGGATTACCTAGGTACT 
5-f  GCTTTTTTGCTTTTACTGATTAACGT 
248 
5-r  GAGCTGTAATTCATTTTATTCCTAATAGCTC 
6-f  TGATTTGACATAACCCTGAGCTTT 
235 
6-r  AACTACCTATTTTTATACCCACAAACAAGA 
7-f  AAGAAAGCCTACACCATTTTTGC 
251 
7-r  GGTAAGATTTATAGATCATTCTTAGAACCAT 
8-f  ACCTATAGTCTAAATTATACCATCTATAATGTGCT 
184 
8-r  GTCATGGCATTAGTGACCAGG 
9-f  AGTCGTAATTTTGTTTCTAAACTCATTTG 
458 
9-r  GCTTTGAAACATGCACTACGATG 
10-f  AAACATCATTGCTCTTCAAATAACAA 
217 
10-r  CTACCATGATTTAAAAATCCACCAGT 
11-f  TTAGATGATTGTCTTTTTCCTCTTGC 
217 
11-r  TGAGCTATCTTAAGAAATACATGTTATAAAAACA 
12-f  GGCTTCAAGTTGTCTTTTTAATGATC 
186 
12-r  AGACCCTGCCTCAAAGAAAAAG 
13-f  TTTCTATTCTTACTGCTAGCATTAAAAACA 
307 
13-r  AATACACAGGTAAGAAATTAGGAAATCTCAT 
14-f  ACTCTAATTAGATGACCCATATTCTGTTTC 
316 
14-r  CAATTAGGTCTTTTTGAGAGTATGAATTCT 
15a-f  GTTACTGCATACACATTGTGACCTTAATTT 
453 
15a-r  CGATGAGATGCCTTGGGACTT 
15b-f  GCGAAGTACAAGGATGCCAATATT 
449 
15b-r  GCAGTGGTGGAGATCTGCAAA 
15c-f  CAACTACCATCCAGCAACAGAAAAT 
491 
15c-r  TTGGTGTATCTAGTTCTCCATCATTATCAT 
15d-f  TCAATACCCAGCCGACCTAGC 
527 
15d-r  CCACATGACGTTTCTCTTCATTATATTTT 
15e-f  GTAAGCCAGTCTTTGTGTCAAGAAGAT 
478 
15e-r  CAGCTGATGACAAAGATGATAATGAAC 
15f-f  CTTGCAAAGTTTCTTCTATTAACCAAGA 
454 
15f-r  CGACTCTCAAAACTATCAAGTGAACTG 
15g-f  ACCTGAACACTATGTTCAGGAGACC 
524 
15g-r  CATTTGATTCTTTAGGCTGCTCTGATT 
15h-f  ACAGAAAGATGTGGAATTAAGAATAATGC 
476 
15h-r  CTCCTTCTCCAGCAGCTAACTCAT 
15i-f  ACATCTCTAAGTGATCTAACAATCGAATC 
650 
15i-r  TCATCATCATCAAAATCTAGAGAACTCA 
15l-f  CTATTGAAGGAACTCCTTACTGTTTTTC 
669 
15l-r  TGCCACCCATATTTCTGGG 
15m-f  GCCTTCAAGACTCAAGGGTGA 
657 
15m-r  GGAGAAGTGGTGGCTGTTTG 
15n-f  CCTTAAGACTCCAGCCTCCAA 
656 
15n-r  GTCTAGATGATGGAGAAAGAGATTCAA 
15o-f  CAACCTTAAGAAGAAAATTGGAGGA 
664 
15o-r  GATCTAGGATTGTTAATGGGACAGTC 
15p-f  TGCTGTTTCTAAAACAGAGGATGTT 
663 
15p-r  AGTTTCATTTGAAACAAAATGTCTATATAGC 238 
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